CIBC World Markets Inc. raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 15.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 103,875 shares of the company’s stock after purchasing an additional 13,513 shares during the period. CIBC World Markets Inc.’s holdings in Novo Nordisk A/S were worth $7,256,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in NVO. Pacer Advisors Inc. bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $1,143,000. NEXT Financial Group Inc bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $30,000. Sequoia Financial Advisors LLC bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $213,000. MAI Capital Management boosted its stake in Novo Nordisk A/S by 6.9% in the third quarter. MAI Capital Management now owns 12,561 shares of the company’s stock valued at $872,000 after acquiring an additional 815 shares during the last quarter. Finally, Clear Harbor Asset Management LLC bought a new position in shares of Novo Nordisk A/S during the third quarter worth $28,000. 5.91% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NVO stock opened at $72.75 on Tuesday. The company has a current ratio of 1.04, a quick ratio of 0.78 and a debt-to-equity ratio of 0.04. Novo Nordisk A/S has a 1 year low of $49.24 and a 1 year high of $75.86. The firm’s fifty day moving average price is $72.04 and its two-hundred day moving average price is $69.23. The firm has a market capitalization of $171.31 billion, a P/E ratio of 27.35, a PEG ratio of 2.21 and a beta of 0.46.
A number of equities analysts have recently weighed in on NVO shares. UBS Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 11th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Novo Nordisk A/S in a research report on Thursday, November 12th. Societe Generale reissued a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, November 3rd. Credit Suisse Group cut shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Wednesday, January 20th. Finally, Barclays reissued an “overweight” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 4th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $72.00.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.